Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. TEM led at +41.77% ($57.72 → $81.83), closing 84.03% of its range with a 4.72x realized/implied ratio — the period's biggest volatility surprise, meaning options pricing badly underpriced the actual swing. MRNA (+35.65%) and EBS (+28.18%) rounded out the upside, with MRNA closing 91.54% of its range, the strongest finish in the report, and posting the highest realized vol among gainers (81.63%).

On the downside, KPTI fell 39.95% ($2.07 → $1.24) but rebounded to close at 76.36% of range. CDXS (-25.07%) is the clearest case of overpriced risk: 335.94% implied against 52.95% realized, a 0.35x ratio. DBVT (0.64x) and QURE (0.84x) show the same pattern — very high implied vol in small caps that under-delivered.

Conversely, SYK (3.29x) and AMGN (2.85x) saw realized vol far exceed implied, both with double-digit negative period returns. Managed care and pharma closed weak: CVS at 3.54% of range, BMY at 7.44%, HUM at 8.73%, SYK at 11.01%, CI at 11.45%. XLV itself fell 5.37% with just 14.43% realized vol.

Broader Market Context

Differential behavior within the sector. The spread between the best and worst names here — roughly 82 percentage points from TEM to KPTI — is far wider than the 5.37% decline in XLV, the sector benchmark. That gap is the story: the index-level move was mild and low-volatility (14.43% realized), while individual constituents whipsawed. Large-cap defensives clustered tightly around modest losses (JNJ -7.25%, MRK -6.79%, LLY -6.31%, ABBV actually +8.04%), while smaller biotech and device names (KPTI, CDXS, STIM, QURE, DBVT) posted double-digit declines on implied vols above 100%. Managed care split off as its own distressed cohort late in the window — UNH, HUM, CVS and CI all closed near range lows — even as CNC and ELV showed positive change figures, suggesting intra-group differentiation rather than a uniform payer selloff.

Rotation vs. idiosyncratic moves. This does not read cleanly as a defensive rotation *into* healthcare; XLV declined and the mega-cap pharma complex drifted lower, which is more consistent with money leaving defensive healthcare exposure in favor of risk-on areas elsewhere. But the sheer dispersion argues that most of the action was stock-specific. TEM's 4.72x and MRNA's 2.61x realized/implied ratios, SYK's -16.90% period return with 3.29x, and AMGN's 2.85x are the signatures of single-name catalysts — the kind of gap-and-hold behavior associated with data readouts, guidance revisions, or deal speculation — rather than a factor-level bid or exit.

Plausible sector-relevant backdrop. Several themes could plausibly relate to what the data shows:

• Policy and reimbursement uncertainty — ongoing drug pricing negotiation frameworks, Medicare Advantage rate assumptions, and exchange subsidy debates disproportionately affect payers and would be consistent with the weak managed-care closes (CVS, HUM, UNH near range lows).
• Binary clinical and regulatory events — the extreme implied vols on CDXS (335.94%), KPTI (194.92%), DBVT (130.66%) and QURE (107.21%) are typical of names with pending catalysts; the fact that most realized far *less* than implied suggests risk premium decayed without resolution.
• Rate and duration sensitivity — small-cap biotech remains among the most rate-sensitive cohorts, and the concentrated weakness there is consistent with a less accommodative discount-rate backdrop.
• M&A and consolidation chatter — persistent speculation around oncology and diagnostics assets could plausibly underpin upside outliers like TEM.